Karen Seiter, MD
Hematology & Oncology · Hawthorne, NYNPI 1265494124
Payments from drug & device makers
Across 540 payments — averaging $2046.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$238K
- Jazz Pharmaceuticals Inc.$177K
- Bristol Myers Squibb$166K
- Novartis$148K
- Genentech, Inc.$116K
- Sanofi$46K
- plus $214K from 26 others
Across 3 payments — averaging $480.86 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$1K
What the payments were for
- Consulting fees$99,97017%
- Speaking & faculty fees$418,48571%
- Travel & lodging$62,19910%
- Food & beverage$11,7232%
- Education$1940%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 146 | $237,697 |
| Jazz Pharmaceuticals Inc. | 56 | $176,917 |
| Bristol Myers Squibb | 41 | $166,431 |
| Novartis | 96 | $148,298 |
| Genentech, Inc. | 12 | $115,946 |
| Sanofi | 25 | $45,895 |
| Agios Pharmaceuticals, Inc. | 27 | $41,294 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $35,127 |
| AstraZeneca | 27 | $23,657 |
| Servier Pharmaceuticals LLC | 19 | $22,328 |
| Helsinn Healthcare SA | 5 | $18,395 |
| Blueprint Medicines Corporation | 11 | $14,012 |
| Daiichi Sankyo Inc. | 20 | $13,068 |
| Astellas Pharma US Inc | 11 | $12,873 |
| Novo Nordisk | 1 | $9,173 |
| AbbVie | 8 | $5,124 |
| Amgen | 1 | $4,400 |
| E.r. Squibb & Sons, L.L.C. | 3 | $4,205 |
| Genentech USA, Inc. | 4 | $4,096 |
| CTI Biopharma Corp. | 2 | $2,100 |
| Gilead(2 entities) | 2 | $2,052 |
| Seagen Inc. | 1 | $1,200 |
| Astellas Pharma Global Development | 1 | $500 |
| Beone Medicines USA, Inc. | 1 | $150 |
| Rigel Pharmaceuticals, Inc. | 1 | $128 |
| Regeneron Healthcare Solutions, Inc. | 1 | $125 |
| Johnson & Johnson | 1 | $77 |
| Janssen Scientific Affairs, LLC | 1 | $23 |
| Apellis Pharmaceuticals, Inc. | 1 | $23 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
| Beigene USA, Inc. | 1 | $12 |
| ADC Therapeutics America, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,105,352 in reported general payments places this provider in the 85th percentile of 967 hematology & oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 84 | $1,508,238 |
| IdhifaEnasidenib Mesylate | 24 | $801,588 |
| JakafiRuxolitinib Phosphate | 52 | $791,351 |
| BrukinsaZanubrutinib | 37 | $487,807 |
| ImbruvicaIbrutinib | 28 | $475,403 |
| OnuregAzacitidine | 19 | $452,573 |
| TibsovoIvosidenib | 12 | $397,453 |
| SprycelDasatinib | 18 | $366,322 |
| IclusigPonatinib Hcl | 15 | $326,031 |
| PomalystPomalidomide | 13 | $288,919 |
| Lenalidomide | 13 | $155,301 |
| SorafenibSorafenib Tosylate | 12 | $123,111 |
| VenclextaVenetoclax | 37 | $78,504 |
| EliquisApixaban | 20 | $25,382 |
| Acyclovir | 115 | $3,831 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid, Idhifa | $166,431 | $2,309,826108 claims |
| E.r. Squibb & Sons, L.L.C.Onureg, Sprycel, Pomalyst | $4,205 | $1,107,81550 claims |
| Incyte CorporationJakafi | $237,697 | $791,35152 claims |
| Beigene USA, Inc.Brukinsa | $12 | $487,80737 claims |
| Servier Pharmaceuticals LLCTibsovo | $22,328 | $397,45312 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Iclusig | $35,127 | $326,03115 claims |
| AbbVieVenclexta | $5,124 | $78,50437 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 967 hematology & oncology providers in New York.
Other hematology & oncology in Hawthorne
- Bonnie Kiner-StrachanHawthorne$3.3M
- Vicky MakkerNew York$27.1M
- Alison MoskowitzNew York$22.7M
- Ajai ChariNew York$22.4M
- Yelena JanjigianNew York$16.9M
- Alexander LesokhinNew York$11.9M
- John MascarenhasNew York$11.8M
- Maria PalombaNew York$11.6M
- Richard ZunigaBabylon$10.9M
- Scott TagawaNew York$10.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.